Optimal Use Of Aromatase Inhibitors To Battle Hormone-receptor Positive Breast Cancer

Main Category: Breast Cancer
Also Included In: Cancer / Oncology
Article Date: 30 Apr 2009 - 2:00 PDT

email to a friend   printer friendly   opinions  

New studies suggest better outcomes when patients are switched to an aromatase inhibitor after two to three years of tamoxifen or when they start adjuvant therapy with an aromatase inhibitor. The breast cancer community discusses the relative efficacy of the various approaches in hormone-sensitive disease.

Debu Tripathy, MD, from Dallas' University of Texas Southern Medical Center, offers his take on the pros and cons of the variety aromatase inhibitor-based treatment strategies.

Starting treatment with exemestane also considerably improved recurrence-free survival and time to distant metastasis.

The risk decline in recurrence-free survival came in at 15%. The reduction in risk for time to distant metastasis was 19%, according to the results.

"Optimal use of aromatase inhibitors comes into focus"
Caroline Helwick
www.cancernetwork.com/display/article/10165/1407843

Source
Cancer Network

• Additional
• References
• Citations